MATCH Treatment Subprotocol Z1C: Phase II Study of Palbociclib (PD-0332991) in Patients with Tumors with CDK4 or CDK6 Amplification and Rb Protein Expression by IHC
(See required screening study ECOG-ACRIN EAY131)
EAY131 (MATCH) Subprotocol Z1C, is closed to accrual effective May 25, 2021.